Article

Childhood Sleep Issues Foreshadow Psychosis, Borderline Personality Disorder

Author(s):

Shorter nighttime sleep duration and later bedtime at 3.5 years old age were significantly associated with borderline personality disorder symptoms.

Isabel Morales-Munoz, PhD

Isabel Morales-Munoz, PhD

Identifying some behavioral sleep issues early on in childhood could help mediate future psychosis or symptoms of borderline personality disorder (BPD).

A team, led by Isabel Morales-Munoz, PhD, Department of Public Health Solutions, National Institute for Health and Welfare in Finland, examined the prospective links between several parent-reported sleep problems in early childhood and psychotic and borderline personality symptoms at 11-13 years old.

The researchers also identified the potential for mediation of the associations by depression at 10 years old.

While persistent childhood nightmares have been prospectively linked to psychosis and borderline personality disorder in adolescence, the extent this association is also true for behavioral sleep problems remains unknown with the potential mechanisms unexplored.

In the study, the investigators assessed 13,488 individuals from the Avon Longitudinal Study of Parents and Children birth cohort, where each participant was followed up with for more than 13 years. The study included pregnant women with expected delivery dates from April 1991 to December 1992.

The investigators included in the final analysis 7155 participants who reported BPD symptoms.

The team assessed psychotic experiences at 12-13 years old using the Psychosis-Like Symptom Interview. They also tested BPD symptoms at 11-12 years old using the UK Childhood Interview for DSM-IV Borderline Personality Disorder.

Parents reported nighttime sleep duration, night awakening frequency, bedtime, and regularity of sleep routines for 6, 18, and 30 months, as well as 3.5, 4.8, and 5.8 years of age.

Higher night awakening frequency at 18 months (OR, 1.13; 95% CI, 1.01-1.26) and less regular sleep routines at 6 months (OR, 0.68; 95% CI, 0.50-0.93), 30 months (OR, 0.64; 95% CI, 0.44-0.95), and 5.8 years of age (OR, 0.32; 95% CI, 0.19-0.53) were significantly linked to psychotic experiences in adolescence.

On the other hand, shorter nighttime sleep duration (OR, 0.78; 95% CI, 0.66-0.92) and later bedtime at 3.5 years old age (OR, 1.32; 95% CI, 1.09-1.60) were significantly associated with borderline personality disorder symptoms.

A mediation analysis showed consistency with all of the previous association, except for the later bedtime at 3.5 years old and BPD in adolescence, which showed no association.

Depression at 10 years old mediated the associations between frequent night awakenings at 18 months of age (bias-corrected estimate, -0.005; 95% CI, -0.008 to -0.002; P = 0.002) and irregular sleep routines at 5.8 years of age (bias-corrected estimate, -0.006; 95% CI, -0.010 to -0.003; P = 0.003) with psychosis.

“The findings suggest that some behavioral sleep problems in childhood are distinctively associated with the onset of psychosis and BPD in adolescence, following different pathways,” the authors wrote. “Furthermore, depression at 10 years of age may mediate only the association with psychosis. These findings contribute to the design of more personalized interventions in psychosis and BPD.”

Sleep is a known factor associated with developmental psychopathologic symptoms and is considered a fundamental operating state of the central nervous system. The potential association of sleep with frontal lobe function is especially relevant in early childhood, when the brain shows substantial dynamic plasticity.

Early behavioral sleep problems could be modifiable risk factors linked to future psychopathologic symptoms.

The study, “Association of Parent-Reported Sleep Problems in Early Childhood With Psychotic and Borderline Personality Disorder Symptoms in Adolescence,” was published online in JAMA Psychiatry.

Related Videos
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Developing Risk Assessment Tools for Viruses in School
© 2024 MJH Life Sciences

All rights reserved.